Exploring New DTx Seeds Through Joint Research
First written in FY2022-Q2. 9 of 12 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「In our initiatives with academia, we will continue to strengthen research and development activities that contribute to unmet medical needs and the sustainability of healthcare.」
The company continues its policy of strengthening research and development that contributes to unmet needs and the sustainability of healthcare through initiatives with academia. - FY2025-H1RestatedAnnual report
「In our initiatives with academia, we will continue to strengthen research and development activities that contribute to unmet medical needs and the sustainability of healthcare.」
The company continues its policy of strengthening research and development that contributes to unmet needs and the sustainability of healthcare through initiatives with academia. - FY2024-Q3RestatedAnnual report
「Going forward, the company will continue to actively promote joint research with many universities and research institutions to create new value by incorporating external knowledge based on the expertise accumulated internally to date.」
The company continues its policy of conducting joint research that combines its internal expertise with knowledge from universities and research institutions to create new value. - FY2024-Q2RestatedAnnual report
「Going forward, the company will continue to actively promote joint research with many universities and research institutions to create new value by incorporating external knowledge based on the expertise accumulated internally to date.」
The company continues its policy of conducting joint research that combines its internal expertise with knowledge from universities and research institutions to create new value. - FY2024-Q1RestatedAnnual report
「Going forward, the company will continue to actively promote joint research with many universities and research institutions to create new value by incorporating external knowledge based on the expertise accumulated internally to date.」
The company continues its policy of conducting joint research that combines its internal expertise with knowledge from universities and research institutions to create new value. - FY2023RestatedAnnual report
「Going forward, the company will continue to actively promote joint research with many universities and research institutions to create new value by incorporating external knowledge based on the expertise accumulated internally to date.」
The company continues its policy of creating new value and pipelines through joint research with universities and research institutions. - FY2023-Q3RestatedAnnual report
「In joint research with academia and other institutions, new initiatives with Nagoya City University, Yokohama City University, the National Center of Neurology and Psychiatry, and others were selected for programs operated by the Japan Agency for Medical Research and Development (AMED) and the Japan Science and Technology Agency (JST). Going forward, the company will continue to actively promote joint research with many universities and research institutions to create new value by incorporating external knowledge based on the expertise accumulated internally to date.」
The company continues its policy of creating new value through joint research with universities and research institutions and the selection of its projects for AMED and JST programs. - FY2023-Q2AdvancedAnnual report
「In joint research with academia and other institutions, new initiatives with Nagoya City University, Yokohama City University, the National Center of Neurology and Psychiatry, and others were selected for programs operated by the Japan Agency for Medical Research and Development (AMED) and the Japan Science and Technology Agency (JST).」
The company reported concrete progress in its joint research with multiple universities and research institutions through the selection of its projects for AMED and JST programs. - FY2023-Q1RestatedAnnual report
「The company is also conducting joint research with multiple medical institutions and pursuing the acquisition of the next pipeline.」
The company continues its policy of pursuing the acquisition of the next pipeline through joint research with multiple medical institutions. - FY2022AdvancedAnnual report
「The company also entered into a joint research agreement with Nagoya City University for the development of a clinical trial app for functional disorders and a joint research agreement with Hamamatsu University School of Medicine to discover new seeds for therapeutic apps.」
In addition to new seed discovery with Hamamatsu University School of Medicine, the company has entered into a joint research agreement with Nagoya City University for a clinical trial app for functional disorders. - FY2022-Q3RestatedAnnual report
「The company entered into joint research agreements with Hamamatsu University School of Medicine to discover new seeds for therapeutic apps and with Tohoku University regarding the use of a clinical trial system incorporating blockchain technology.」
The company continues its policy of discovering new seeds, including through joint research with Hamamatsu University School of Medicine. The agreement with Tohoku University is recorded separately as a new theme. - FY2022-Q2AdvancedAnnual report
「In addition, the company entered into a joint research agreement with Hamamatsu University School of Medicine to discover new seeds.」
The company identifies the conclusion of a joint research agreement with Hamamatsu University School of Medicine as a specific initiative to acquire new pipelines.